Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.

Trial Details

NCT ID
NCT04520932
Phase
NA
Sponsor
Institut Paoli-Calmettes
Status
RECRUITING
Cancer Type
Pancreatic Neuroendocrine Pancreatic Cancer
Interventions
  • Radiofrequency ablation
Locations (sample)
  • Marseille, France|43.29695,5.38107

Key Eligibility Criteria

  • Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
  • Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\<3%,
  • Non-secretory lesion.
  • Homogeneous HEE contrast taking;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Neuroendocrine Pancreatic Cancer Trials on Trialify →